Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
27 April 2021Website:
http://www.protagenic.comNext earnings report:
01 April 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | 118 min agoDividend
Analysts recommendations
Institutional Ownership
PTIX Latest News
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today that on November 4, 2024 it closed its previously announced private placement pursuant to a purchase agreement (the "Purchase Agreement") for the purchase and sale of an aggregate of 1,948,295 shares of common stock, series A common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock, with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date (as defined in the Purchase Agreement) for a term of eighteen (18) months from the Stockholder Approval Date, and series B common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date for a term of five (5) years from the Stockholder Approval Date. The purchase price of each share of common stock and associated common stock purchase warrants was $0.64 ($0.89 in the case of insiders).
Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript
Call Scheduled for Monday, April 1st, 2024, at 4:30 pm ET NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Company plans to hold its first investor earnings call to discuss the results contained in its FY 2023 Form 10K, which it plans to file that day, and its outlook for FY 2024. The Company plans to hold its earnings call, open to the public, at 4:30 pm ET on Monday, April 1st, to discuss the results of its Q4 and FY 2023, which it plans to publish in its Form 10K to be filed with the SEC that day.
What type of business is Protagenic Therapeutics?
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
What sector is Protagenic Therapeutics in?
Protagenic Therapeutics is in the Healthcare sector
What industry is Protagenic Therapeutics in?
Protagenic Therapeutics is in the Biotechnology industry
What country is Protagenic Therapeutics from?
Protagenic Therapeutics is headquartered in United States
When did Protagenic Therapeutics go public?
Protagenic Therapeutics initial public offering (IPO) was on 27 April 2021
What is Protagenic Therapeutics website?
https://www.protagenic.com
Is Protagenic Therapeutics in the S&P 500?
No, Protagenic Therapeutics is not included in the S&P 500 index
Is Protagenic Therapeutics in the NASDAQ 100?
No, Protagenic Therapeutics is not included in the NASDAQ 100 index
Is Protagenic Therapeutics in the Dow Jones?
No, Protagenic Therapeutics is not included in the Dow Jones index
When was Protagenic Therapeutics the previous earnings report?
No data
When does Protagenic Therapeutics earnings report?
The next expected earnings date for Protagenic Therapeutics is 01 April 2025